Esophageal cancer diagnoses account for just 1.1% of all new cancers each year (per National Cancer Institute). This makes esophageal cancer rarer than breast cancer, prostate cancer, and lung cancer.
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the latest American ...
*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • My daughter suffers terribly from esophageal spasms. She is currently taking Ativan, Bentyl, Pepcid and ...
ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...